Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a ...

Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...

Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 ...

Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a ... or approximately 63 million individuals, have high levels of Lp(a).1,2 Elevated Lp(a) levels can double or even triple ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of ...

1. Family Heart Foundation. Lipoprotein(a) - Family Heart Foundation. Last accessed Nov. 13, 2024. 2. Family Heart Foundation. Diagnosing High Lipoprotein(a) - Family Heart Foundation. Last ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...